Comparing Hybrid, Outpatient, and Network-Based Bispecific Programs

Bispecific antibody therapies are reshaping cancer care, but their delivery models—hybrid, outpatient, and network-based programs—are evolving faster than standard infusion centers can adapt, according to recent industry reports and provider surveys.

A 2026 analysis of emerging treatment pathways by the American Journal of Managed Care (AJMC) highlights how bispecific therapies, including FDA-approved drugs like mosunetuzumab (for lymphoma) and tebentafusp (for melanoma), are driving a shift toward decentralized care models. These programs combine traditional infusion centers with remote monitoring, home-based dosing, and regional hub-and-spoke networks to improve access and reduce patient burden. "The traditional oncology clinic isn’t built for this," said Dr. Emily Carter, director of clinical operations at the Oncology Outcomes Research Consortium, citing a 40% increase in demand for flexible dosing schedules since 2024.

Why are bispecific therapies pushing for new delivery models?
Bispecific antibodies target two distinct proteins on cancer cells, often with higher precision than monoclonal antibodies. However, their complex dosing regimens—sometimes requiring weekly infusions over months—clash with the rigid schedules of hospital-based oncology units. A June 2026 survey of 500 U.S. oncologists by the National Comprehensive Cancer Network (NCCN) found that 68% of respondents reported challenges in accommodating these therapies within existing clinic workflows. "Patients with advanced cancers can’t always travel for treatment," noted Dr. Carter. "We’re seeing a push toward hybrid models where infusions happen in outpatient centers, but follow-up visits and lab work are decentralized."

The shift is also driven by cost pressures. A 2025 study in JAMA Oncology estimated that bispecific therapies cost $150,000 to $250,000 per year per patient—far exceeding the reimbursement rates for standard chemotherapy. Network-based programs, where regional hubs coordinate care across multiple sites, allow insurers and providers to spread fixed costs while maintaining quality. "It’s not just about convenience; it’s about sustainability," said Sarah Mitchell, vice president of oncology at Aetna, which has piloted network programs in five states.

How are hybrid and outpatient programs structured?
Three dominant models are emerging, each tailored to different patient needs:

1. Hybrid Infusion Centers
   These blend traditional oncology clinics with retail-style pharmacies and telehealth check-ins. For example, MD Anderson Cancer Center’s new "Bispecific Therapy Hub" in Houston combines same-day infusion slots with on-site pharmacists who pre-package doses for home administration. "We’ve reduced no-show rates by 22% since implementing this model," said Dr. Raj Patel, the hub’s medical director, citing data from the center’s 2025 patient records.

2. Fully Outpatient Networks
   Companies like USPI Medical and Kindred Healthcare are partnering with oncology groups to open standalone infusion suites in strip malls or urgent-care clinics. These sites offer extended hours and same-day appointments, critical for patients undergoing bispecific therapy who may experience delayed side effects like cytokine release syndrome. A pilot program in Florida, tracked by the American Society of Clinical Oncology (ASCO), showed that outpatient networks reduced emergency-room visits by 35% for patients on bispecifics compared to those treated in hospital-based clinics.

3. Hub-and-Spoke Models
   Large health systems like Cleveland Clinic and Mayo Clinic are testing regional hubs that serve as dosing centers, with "spokes" (smaller clinics or telehealth nodes) handling follow-ups. This approach leverages electronic health records to share real-time data between sites. "The goal is to keep patients close to home while ensuring they don’t fall through the cracks," said Dr. Lisa Wong, chief of hematology at Mayo Clinic’s Arizona campus. Early data from their 2026 program suggest that 78% of patients in rural areas now have access to bispecific therapies, up from 42% in 2024.

What challenges remain for providers and insurers?
Despite the promise of decentralized care, several hurdles persist:

• Reimbursement Complexity
  Bispecific therapies often require prior authorization from insurers, a process that can delay treatment by weeks. A 2026 report by the Leukemia & Lymphoma Society found that 30% of patients faced denials or partial coverage for these drugs, even when clinically indicated. "The billing codes for these therapies are still catching up," said Mitchell of Aetna. "We’re working with CMS to update the fee schedules, but it’s a slow process."

• Workforce Shortages
  Bispecific therapies demand specialized nursing training to manage unique side effects like neurotoxicity or cardiac events. A survey by the Oncology Nursing Society revealed that 56% of oncology nurses reported insufficient preparation to handle these cases. "We’re retraining staff, but the pipeline isn’t keeping up with demand," said Dr. Carter.

• Data Integration Gaps
  Decentralized programs rely on seamless data sharing between hubs, spokes, and electronic health records. However, a 2025 study in Health Affairs found that 40% of oncology practices still use fragmented systems that don’t interoperate. "If a patient’s lab results from a spoke clinic don’t automatically update the hub’s system, we risk missing critical trends," said Dr. Wong.

What’s next for bispecific therapy delivery?
Industry experts predict three key trends in the next 12–18 months:

1. Expansion of Home-Based Dosing
   Companies like BioMarin and Genentech are testing subcutaneous formulations of bispecific antibodies, which could allow patients to self-administer doses at home with minimal supervision. "This could be a game-changer for elderly patients or those in remote areas," said Dr. Patel, though he noted that regulatory approval for home use remains a hurdle.

2. Insurer-Led Network Consolidation
   Payers like UnitedHealthcare and Cigna are expected to launch their own bispecific therapy networks, bundling infusion services with pharmacy benefits to control costs. "We’re seeing the first signs of this in oncology, where insurers are acting as de facto health systems," said Mitchell.

3. Regulatory Clarity on Decentralized Care
   The FDA and CMS are under pressure to update guidelines for off-site infusion programs. In May 2026, the FDA issued draft guidance on remote patient monitoring for targeted therapies, a step toward formalizing decentralized models. "The rules are still being written, but the industry is moving faster than the regulators," said Dr. Wong.

Key Takeaway
Bispecific therapies are not just changing what cancer treatments look like—they’re forcing a rewrite of how those treatments are delivered. While hybrid, outpatient, and network-based programs offer solutions to access and cost barriers, their success hinges on resolving reimbursement, workforce, and data challenges. For patients, the shift means more flexibility; for providers, it demands agility. As Dr. Carter put it: "The future of oncology isn’t just about better drugs—it’s about delivering them in ways that work for real people."